文献速递乳腺癌放疗放疗物理与技术姑息放疗与转移瘤

立体定向消融放疗联合靶向FAPα的癌症疫苗抑制4T1小鼠乳腺癌转移性肿瘤生长

Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer.
PubMed 文献 · Radiother Oncol · 2023-10-06

研究以免疫原性差的转移性小鼠乳腺癌4T1为模型,比较FAPα癌症疫苗、SABR单药及二者联合等五组治疗。结果显示联合治疗耐受良好,显著降低肿瘤负荷并延长生存,且可诱导远隔效应清除肺转移。

要点

  • SABR/FAPα-Vax联合治疗耐受良好,较单药显著降低肿瘤负荷并延长生存。
  • 联合治疗诱导远隔效应,能够清除肺转移灶。
  • 联合治疗招募并激活CD8+ T细胞,促进巨噬细胞向抗肿瘤M1状态极化,并耗竭MDSC与Treg。

核心结论

  • 研究认为放疗联合FAPα癌症疫苗是治疗免疫原性差的转移性癌症有前景的新型治疗组合。
  • 作者认为本研究可能为克服FAPα+癌相关成纤维细胞(CAFs)所致的治疗抵抗开辟道路。

研究设计与样本

  • 研究使用免疫原性差的转移性小鼠乳腺癌4T1模型。
  • 小鼠随机分为五组:未治疗对照、FAPα癌症疫苗、SABR、SABR+pCDH(慢病毒对照载体)、SABR+FAPα癌症疫苗(SABR/FAPα-Vax)。
  • FAPα癌症疫苗每周皮下给药一次,共三次。
  • SABR于首次疫苗接种后对原发肿瘤给予3×8 Gy。

主要发现

  • 接受FAPα癌症疫苗或SABR单药治疗的荷瘤小鼠肿瘤体积轻度缩小、动物寿命延长。
  • SABR/FAPα-Vax耐受良好,较单药治疗显著降低肿瘤负荷并延长生存。
  • 生存延长与细胞外基质(ECM)生成、肿瘤血管生成及淋巴管生成受抑制相关。
  • SABR/FAPα-Vax产生远隔效应,能够清除肺转移。
  • SABR/FAPα-Vax招募并激活CD8+ T细胞攻击肿瘤细胞和FAPα+基质细胞,并启动抑制性细胞重编程,包括促进巨噬细胞向抗肿瘤M1状态极化以及耗竭髓源性抑制细胞(MDSCs)和调节性T细胞(Tregs)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study tested the hypothesis that a novel combination of stereotactic ablation radiotherapy (SABR) and a cancer vaccine against fibroblast activation protein-alpha (FAPα) can suppress established tumor growth and impede potential metastasis. METHODS: The poorly immunogenic metastatic mouse mammary carcinoma 4T1 was used as a model. Mice were randomly assigned to five treatment groups: (1) untreated control, (2) FAPα-based cancer vaccine, (3) SABR, (4) SABR + pCDH (lentiviral control vector), (5) SABR + FAPα-based cancer vaccine (SABR/FAPα-Vax). FAPα-based cancer vaccine were administered subcutaneously every week for a total of three treatments. SABR was delivered to the primary tumor by 3 × 8 Gy after the first vaccination. RESULTS: Consistent with the poorly immunogenic nature of 4T1, tumor-bearing mice receiving FAPα-based cancer vaccine or SABR monotherapy showed a modest reduction in tumor volume and increased animal lifespan. In contrast, SABR/FAPα-Vax was well-tolerated, significantly reduced tumor burden, and increased survival compared to monotherapy. The increased survival correlated with inhibition of extracellular matrix (ECM) production, tumor vascularization and lymphangiogenesis. SABR/FAPα-Vax also resulted in an abscopal effect capable of eliminating lung metastases. SABR/FAPα-Vax recruited and activated CD8 + T cells to attack tumor cells and FAPα + stromal cells, and initiated suppressor cell reprogramming, including facilitating macrophage polarization toward an anti-tumor (M1) state, as well as depleting myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). CONCLUSION: These findings provide a novel therapeutic combination of radiation and FAPα-based cancer vaccine with promising results against poorly immunogenic metastatic cancer. This study may pave the way to overcome the therapeutic resistance caused by FAPα + CAFs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen M, Xiao L, Jia H, et al. Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer. Radiother Oncol. 2023. PMID: 37806560. doi:10.1016/j.radonc.2023.109946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。